APPENDICURE

Goblet cell adenocarcinoma (GCA) of the appendix sits in an uncomfortable gray zone in oncology.

It is not typical appendix cancer.
It is not classic colon cancer.
It is not purely neuroendocrine.

Yet when it spreads, most patients are still treated using colon cancer chemotherapy regimens.

For a rare and biologically distinct cancer, that should concern all of us.

If we are serious about improving outcomes in GCA, we have to be honest about three things:

1. What the current systemic standards actually are
2. Where immunotherapy realistically fits
3. What biologically rational clinical trials should look like

1. Current Systemic Standards for Metastatic Goblet Cell

There is no FDA-approved, GCA-specific regimen.

Instead, treatment is usually modeled after metastatic colorectal cancer, most commonly:

• FOLFOX (5-FU + leucovorin + oxaliplatin)

• FOLFIRI (5-FU + leucovorin + irinotecan)

• CAPOX (capecitabine + oxaliplatin)

• Sometimes these are combined with bevacizumab

This approach is based on practicality, not precision.

Why colon cancer regimens?

Because:

GCA behaves more like an adenocarcinoma than a classic neuroendocrine tumor.

There are no randomized trials dedicated to GCA.

It is too rare to attract large pharmaceutical development.

But biologically, GCA is not simply colon cancer that happens to live in the appendix.

It has:

Mixed glandular and neuroendocrine features

Distinct molecular characteristics

Unique metastatic patterns (especially peritoneal spread)

Using colon regimens is often reasonable — but it is also an admission that we do not have tailored options.

And for patients, that uncertainty matters.

2. Where Does Immunotherapy Fit (If at All)?

This is where things become even more complex.

Most goblet cell adenocarcinomas are:

• Microsatellite stable (MSS)
• Low tumor mutational burden (TMB)
• Immunologically “cold”

That profile predicts poor response to checkpoint inhibitors like:

• Pembrolizumab
• Nivolumab
• Atezolizumab

For the majority of patients, single-agent immunotherapy is unlikely to work.

When immunotherapy may be appropriate:

• MSI-High (MSI-H) or dMMR tumors
• High TMB
• A biomarker-driven clinical trial

MSI-H in GCA is uncommon, but it must be tested. It is one of the few situations where immunotherapy can meaningfully change outcomes.

Outside of that?
We do not yet have strong evidence that immunotherapy combinations overcome the “cold” biology of goblet cell tumors.

This is not pessimism. It is precision.

3. Clinical Trial Directions That Actually Make Biological Sense for GCA

If we want better treatments, we need to stop pretending GCA is just colon cancer and instead build trials around its biology.

Here are rational directions:

A. Molecularly Targeted Approaches

Comprehensive genomic profiling is critical.

Potential actionable targets may include:

• KRAS mutations
• TP53 alterations
• Rare but actionable fusions
• DNA damage repair pathway alterations

Basket trials based on mutation — not tumor location — may be more promising than colon-based protocols.

B. Combination Immunotherapy for “Cold” Tumors

Since most GCA is MSS and immunologically quiet, future strategies should focus on:

• Checkpoint inhibitor + MEK inhibitor
• Checkpoint inhibitor + anti-angiogenic therapy
• Checkpoint inhibitor + TGF-beta modulation
• Tumor microenvironment targeting

Not immunotherapy alone — but rational immune priming combinations.

C. Peritoneal-Focused Strategies

Because GCA frequently spreads within the peritoneum:

• HIPEC optimization studies
• Intraperitoneal chemotherapy approaches
• Novel drug delivery platforms

Peritoneal biology deserves dedicated research in goblet cell — not borrowed assumptions.

D. Neuroendocrine-Informed Research

GCA has hybrid features. It is neither fully adenocarcinoma nor fully neuroendocrine.

This raises important questions:

• Are there subsets that respond to platinum-based regimens?
• Should high-grade GCA be treated more like aggressive neuroendocrine carcinoma?
• Are there peptide receptor or neuroendocrine pathway targets worth exploring?

These are unanswered questions because no one has designed trials specifically for GCA.

The Core Problem

Goblet cell adenocarcinoma is rare.

Rare cancers are routinely managed by extrapolation:

• “Close enough” histology
• “Similar enough” organ
• “Good enough” data

But “close enough” is not the same as evidence.

When patients are treated as colon cancer because it is convenient for the system, not because it is biologically correct, progress slows.

We need:

• Dedicated registries
• Molecular databases
• Collaborative rare tumor trials
• Funding that reflects unmet need

Goblet cell patients should not be an afterthought inside colorectal algorithms.

What Patients Can Do to Help Advance GCA Research

Goblet cell adenocarcinoma is rare. That means progress depends heavily on patient participation in research efforts.

There are several practical ways patients can help move the science forward.

1. Get Comprehensive Molecular Testing

Every GCA patient should ask their care team about next-generation sequencing (NGS) of their tumor.

Genomic profiling can identify:

• KRAS, TP53, and other common mutations
• Rare actionable alterations
• DNA repair defects
• Biomarkers that qualify patients for clinical trials

Even when a mutation does not immediately change treatment, it contributes to the growing understanding of GCA biology.

For rare cancers, every sequenced tumor helps build the evidence base.

2. Contribute to Rare Tumor Registries

Patient registries are one of the most powerful tools for studying rare diseases.

Registries allow researchers to analyze:

• Treatment patterns
• Survival outcomes
• Molecular features
• Patterns of spread

Without aggregated patient data, it is almost impossible to design better trials.

Participating in registries helps transform individual experiences into research-grade evidence.

3. Consider Clinical Trials When Appropriate

Clinical trials are how new treatments are discovered.

Because GCA is rare, patients may be eligible for several types of trials:

• Basket trials based on genetic mutations
• Immunotherapy combination trials
• Peritoneal-directed therapy studies
• Rare tumor or appendix cancer trials

Even small trials can generate insights that eventually lead to new standards of care.

4. Preserve Tumor Tissue When Possible

Stored tumor tissue allows researchers to perform:

• molecular analysis
• immune profiling
• biomarker discovery

If additional surgeries or biopsies occur, patients can ask whether samples can be banked for research.

Biobanks are essential for studying rare cancers.

5. Share Outcomes With the Research Community

Many breakthroughs in rare cancers start with carefully documented patient outcomes.

This includes:

• contributing data to registries
• participating in observational studies
• allowing anonymized data sharing

When enough cases are documented, patterns begin to emerge that can guide future treatment strategies.

Why Patient Participation Matters

For common cancers, thousands of patients enter trials every year.

For goblet cell adenocarcinoma, researchers may see only a handful of cases annually at any single institution.

That means every patient who contributes data, tissue, or trial participation is helping build the scientific foundation needed to design better treatments.

Progress in rare cancers is rarely fast.

But it becomes possible when patients, physicians, and researchers work together to build the evidence that does not yet exist.

Why Advocacy Matters in Rare Cancers

In common cancers, research systems are already built.

In rare cancers like goblet cell adenocarcinoma, patients often help build the system itself.

Every tumor sequenced, every registry entry, every clinical trial participant, and every shared outcome contributes to the knowledge base that physicians rely on to treat the next patient.

Progress in rare cancers rarely begins in large pharmaceutical programs. It begins with patients, clinicians, and researchers working together to generate the data that does not yet exist.

Goblet cell adenocarcinoma patients deserve treatments designed for their disease.

And the path to those treatments starts with building the evidence….together.

If you or your loved one has been diagnosed with GCA, please share where you are being treated. (If you replied to Molly’s Survey on Facebook you do not need to reply here.)